Retrophin Inc (OQ:RTRX)

Business Focus: Bio Therapeutic Drugs

Aug 22, 2019 06:00 am ET
Retrophin Announces Topline Results from Phase 3 FORT Study of Fosmetpantotenate in Patients with PKAN
Retrophin, Inc. (NASDAQ: RTRX) today announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration (PKAN) did not meet its primary...
Aug 06, 2019 04:01 pm ET
Retrophin Reports Second Quarter 2019 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today reported its second quarter 2019 financial results and provided a corporate update. The Phase 3 FORT Study evaluating fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration...
Jul 31, 2019 04:30 pm ET
Retrophin to Present at Canaccord Genuity’s 39th Annual Growth Conference
Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7, 2019 at 8:30 a.m. ET. A live webcast of the...
Jul 23, 2019 04:30 pm ET
Retrophin to Report Second Quarter 2019 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2019 financial results on Tuesday, August 6, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the...
Jun 28, 2019 04:34 pm ET
Retrophin Announces FDA Approval of THIOLA® EC (tiopronin) 100mg and 300mg Tablets for the Treatment of Cystinuria
Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has approved 100 mg and 300 mg tablets of THIOLA® EC (tiopronin), a new enteric-coated formulation of THIOLA® (tiopronin), to be used for the treatment...
Jun 18, 2019 04:30 pm ET
Retrophin Announces Cooperative Research and Development Agreement with NCATS and the Alagille Syndrome Alliance to Identify Potential Therapeutics for Alagille Syndrome
Retrophin, Inc. (NASDAQ: RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and...
May 30, 2019 04:30 pm ET
Retrophin to Present at Upcoming Investor Conferences
Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming investor conferences in June: Jefferies 2019 Global Healthcare ConferenceDate: Tuesday, June 4, 2019Time: 10:30 a.m. ETLocation: New York...
May 13, 2019 08:00 am ET
Retrophin Appoints Sandra E. Poole to Board of Directors
Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Sandra E. Poole to the Company's Board of Directors, effective immediately. Ms. Poole brings more than 25 years of biopharmaceutical industry experience in manufacturing strategy,...
May 07, 2019 04:01 pm ET
Retrophin Reports First Quarter 2019 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today reported its first quarter 2019 financial results and provided a corporate update. Top-line data from the pivotal Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase-associated neurodegeneration...
Apr 23, 2019 04:30 pm ET
Retrophin to Report First Quarter 2019 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial...
Mar 06, 2019 08:15 am ET
Detailed Research: Economic Perspectives on KAR Auction Services, Spectrum Brands, Vertex Pharmaceuticals, The Kraft Heinz, comScore, and Retrophin — What Drives Growth in Today's Competitive Landscap
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of KAR Auction Services, Inc (NYSE:KAR), Spectrum Brands Holdings Inc. (NYSE:SPB),...
Mar 05, 2019 04:30 pm ET
Retrophin to Present at Upcoming Investor Conferences
Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March: Cowen & Company 39th Annual Health Care ConferenceDate: Tuesday, March 12,...
Feb 28, 2019 08:00 am ET
Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and others worldwide to recognize Rare Disease Day® 2019. This year's theme, "Bridging health...
Feb 26, 2019 04:01 pm ET
Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today reported its fourth quarter and full year 2018 financial results and provided a corporate update. The Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase-associated neurodegeneration (PKAN)...
Feb 14, 2019 04:30 pm ET
Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 3:30 p.m. ET. A live webcast...
Feb 12, 2019 04:30 pm ET
Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to...
Feb 04, 2019 07:35 am ET
Analysis: Positioning to Benefit within Amarin, Retrophin, Sunrun, BioSpecifics Technologies, Arbutus Biopharma, and TOCAGEN INC — Research Highlights Growth, Revenue, and Consolidated Results
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Retrophin, Inc. (NASDAQ:RTRX),...
Jan 07, 2019 07:00 am ET
Retrophin Provides Corporate Update and 2019 Outlook
Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2018 to be approximately $44 million. For the fiscal year 2018, the Company...
Jan 03, 2019 04:30 pm ET
Retrophin Names Eric Dube, Ph.D. President and Chief Executive Officer
Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Eric Dube, Ph.D. as president and chief executive officer, effective January 4, 2019. Dr. Dube joins Retrophin from ViiV Healthcare, where he served as president of North America,...
Jan 02, 2019 04:30 pm ET
Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 10, 2019 at 11:00 a.m. PT (2:00 p.m. ET). A live...
Dec 27, 2018 08:00 am ET
Retrophin Doses First Patient in Pivotal Phase 3 PROTECT Study of Sparsentan for the Treatment of IgA Nephropathy
Retrophin, Inc. (NASDAQ: RTRX) today announced that the first patient has been dosed in the PROTECT Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan for the treatment of IgA...
Dec 20, 2018 08:00 am ET
Retrophin Completes Enrollment of Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN
Retrophin, Inc. (NASDAQ: RTRX) today announced completion of patient enrollment in the pivotal Phase 3 FORT Study, which is evaluating the safety and efficacy of fosmetpantotenate for the treatment of pantothenate kinase-associated...
Nov 28, 2018 04:30 pm ET
Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference
Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO 2018 Prescriptions for Success Healthcare Conference in New York City on Wednesday, December 12, 2018 at 9:20 a.m. ET. A live...
Nov 28, 2018 08:50 am ET
Report: Developing Opportunities within Liberty TripAdvisor, Chanticleer, Retrophin, Menlo Therapeutics, Shire plc, and Matthews International — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Liberty TripAdvisor Holdings, Inc. (NASDAQ:LTRPA), Chanticleer...
Nov 12, 2018 07:00 am ET
Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for a new formulation of Thiola (tiopronin) in the treatment of cystinuria. The FDA has assigned...
Nov 07, 2018 04:30 pm ET
Retrophin to Present at the Jefferies 2018 London Healthcare Conference
Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare Conference in London, UK on Wednesday, November 14, 2018 at 4:40 p.m. GMT (11:40 a.m. ET). A live...
Nov 01, 2018 04:01 pm ET
Retrophin Reports Third Quarter 2018 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2018 financial results and provided a corporate update. Phase 3 FORT Study of fosmetpantotenate in pantothenate kinase-associated neurodegeneration (PKAN) continues toward...
Oct 29, 2018 08:44 pm ET
Robbins Arroyo LLP Is Investigating the Officers and Directors of Retrophin, Inc. (RTRX) on Behalf of Shareholders
Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Retrophin, Inc. (NASDAQ: RTRX) breached their fiduciary duties to shareholders. Retrophin is a biopharmaceutical company that focuses on the development and commercialization of therapies for the tre
Oct 26, 2018 09:18 pm ET
Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Retrophin, Inc. (NASDAQ: RTRX) today announced new positive data from the ongoing open-label extension of the Phase 2 DUET Study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS), a rare kidney disorder that often leads...
Oct 25, 2018 04:01 pm ET
Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology
Retrophin, Inc. (NASDAQ: RTRX) today announced that the Journal of the American Society of Nephrology (JASN) has published online (doi: 10.1681/ASN.2018010091) the positive results from the Phase 2 DUET Study of sparsentan for the treatment of...
Oct 19, 2018 09:10 am ET
New Research: Key Drivers of Growth for Teva Pharmaceutical Industries, Axovant Sciences, SolarEdge Technologies, NantHealth, Kosmos Energy, and Retrophin — Factors of Influence, Major Initiatives and
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Axovant Sciences Ltd....
Oct 18, 2018 04:30 pm ET
Retrophin to Report Third Quarter 2018 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2018 financial results on Thursday, November 1, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the...
Oct 05, 2018 04:01 pm ET
Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018
Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental glomerulosclerosis (FSGS), at the American Society of Nephrology (ASN) Kidney Week 2018. The Company will...
Oct 03, 2018 04:30 pm ET
Retrophin to Highlight Fosmetpantotenate Program for PKAN at Upcoming Medical Congresses
Retrophin, Inc. (NASDAQ: RTRX) today announced that presentations highlighting the design of the ongoing pivotal Phase 3 FORT Study of fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), the patient and...
Sep 27, 2018 04:30 pm ET
Retrophin Announces Upcoming Presentations at the 15th International Symposium on IgA Nephropathy
Retrophin, Inc. (NASDAQ: RTRX) today announced two upcoming presentations related to its development program for sparsentan in the treatment of IgA nephropathy (IgAN), a rare kidney disorder often resulting in end-stage renal disease, during the...
Sep 17, 2018 04:30 pm ET
Retrophin to Present at Upcoming Investor Conferences
Retrophin, Inc. (NASDAQ: RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in October: Cantor Global Healthcare ConferenceDate: Monday, October 1, 2018Time: 4:40 p.m. ETLocation:...
Sep 05, 2018 08:32 pm ET
Retrophin Prices Upsized $240 Million Convertible Senior Notes Offering
Retrophin, Inc. (NASDAQ: RTRX) today announced the pricing of its offering of $240 million aggregate principal amount of 2.50% convertible senior notes due 2025 (the “notes”) to be sold in an underwritten offering. The sale of the notes is expected...
Sep 04, 2018 04:07 pm ET
Retrophin Announces Proposed Convertible Senior Notes Offering
Retrophin, Inc. (NASDAQ: RTRX) today announced its intention to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2025 (the “notes”) in an underwritten offering. Retrophin also...
Aug 21, 2018 08:15 am ET
New Research Coverage Highlights pdvWireless, Fortuna Silver Mines, Nordic American Tankers, Amarin, Himax Technologies, and Retrophin — Consolidated Revenues, Company Growth, and Expectations for 201
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of pdvWireless, Inc. (NASDAQ:PDVW), Fortuna Silver Mines Inc. (NYSE:FSM),...
Jul 30, 2018 04:30 pm ET
Retrophin Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Noah L. Rosenberg, M.D., as chief medical officer, where he will oversee the clinical development of Retrophin’s product pipeline. Dr. Rosenberg brings to Retrophin more than 20...
Jul 26, 2018 04:05 pm ET
Retrophin Reports Second Quarter 2018 Financial Results and Announces CEO Transition Plan
Retrophin, Inc. (NASDAQ:RTRX) today reported its second quarter 2018 financial results and provided a corporate update. In June 2018, the Company announced the initiation of enrollment for pediatric patients with pantothenate kinase-associated...
Jul 12, 2018 04:30 pm ET
Retrophin to Report Second Quarter 2018 Financial Results
Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2018 financial results on Thursday, July 26, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the...
Jun 14, 2018 08:00 am ET
Retrophin Announces Expansion of Intellectual Property Estate for Sparsentan with Newly Issued U.S. Patent
Retrophin, Inc. (NASDAQ:RTRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a new patent covering the Company’s product candidate sparsentan which, in addition to being in Phase 3 clinical development for the...
Jun 06, 2018 07:50 am ET
Research Report Identifies Corbus Pharmaceuticals, Retrophin, Charter Financial, HighPoint Resources, Southern First Bancshares, and Oaktree Specialty Lending with Renewed Outlook — Fundamental Analys
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), Retrophin, Inc....
Jun 04, 2018 08:00 am ET
Retrophin Announces Pivotal Phase 3 FORT Study of Fosmetpantotenate in PKAN Opens Enrollment to Pediatric Patients
Retrophin, Inc. (NASDAQ:RTRX) today announced that the independent Data Monitoring Committee (DMC) for the pivotal Phase 3 FORT Study, which is evaluating fosmetpantotenate for the treatment of pantothenate kinase-associated neurodegeneration...
May 24, 2018 04:30 pm ET
Retrophin to Present at Upcoming Investor Conferences
Retrophin, Inc. (NASDAQ:RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in June: Jefferies 2018 Global Healthcare ConferenceDate: Thursday, June 7, 2018Time: 9:00 a.m....
May 23, 2018 04:30 pm ET
Retrophin Receives Workplace Excellence Award
Retrophin, Inc. (NASDAQ:RTRX) today announced that it has been awarded the Peter Barron Stark Companies (PBS) Award for Workplace Excellence, which recognizes top-tier organizations committed to a culture of workplace excellence based upon employee...
May 01, 2018 04:01 pm ET
Retrophin Reports First Quarter 2018 Financial Results
Company obtains FDA and EMA feedback on pathway to NDA and MAA filing for sparsentan in IgA nephropathy; single Phase 3 trial expected to initiate in the fourth quarter of 2018
Apr 17, 2018 04:30 pm ET
Retrophin to Report First Quarter 2018 Financial Results
SAN DIEGO, April 17, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report first quarter 2018 financial results on Tuesday, May 1, 2018 after the close of the U.S. financial markets. The Company will host...
Apr 12, 2018 08:10 am ET
New Research Coverage Highlights Woori Bank, Texas Capital Bancshares, Retrophin, SPS Commerce, Corbus Pharmaceuticals, and EnPro Industries — Consolidated Revenues, Company Growth, and Expectations f
NEW YORK, April 12, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Woori Bank (NYSE:WF), Texas Capital Bancshares,...
Apr 03, 2018 08:00 am ET
Retrophin Initiates Pivotal Phase 3 Clinical Trial of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
SAN DIEGO, April 03, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been enrolled in the DUPLEX Study, a global, pivotal Phase 3 clinical trial evaluating the long-term nephroprotective potential of sparsentan...
Mar 16, 2018 07:35 am ET
Analysis: Positioning to Benefit within Capella Education, Access National, Randgold Resources, Diodes, Silicon Motion Technology, and Retrophin — Research Highlights Growth, Revenue, and Consolidated
NEW YORK, March 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capella Education Company (NASDAQ:CPLA), Access National...
Mar 05, 2018 04:30 pm ET
Retrophin Announces Appointment of Casey Logan as Vice President of Corporate Development
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Casey Logan has joined the Company as vice president, corporate development. Mr. Logan will report to chief operating officer Neil McFarlane, and be responsible...
Feb 28, 2018 04:30 pm ET
Retrophin to Present at the Barclays Global Healthcare Conference
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 14, 2018 at 3:50 p.m. ET.
Feb 27, 2018 04:01 pm ET
Retrophin Reports Fourth Quarter and Full Year 2017 Financial Results
Company gains alignment to proceed on Subpart H accelerated approval pathway for sparsentan in FSGS; Study start-up activities ongoing to initiate Phase 3 pivotal trial in second quarter of 2018
Feb 27, 2018 12:50 pm ET
Retrophin, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 27, 2018 / Retrophin, Inc. (NASDAQ: RTRX) will be discussing their earnings results in their Q4 Earnings Call to be held on February 27, 2018 at 4:30 PM Eastern Time.
Feb 13, 2018 04:30 pm ET
Retrophin to Report Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report fourth quarter and full year 2017 financial results on Tuesday, February 27, 2018 after the close of the U.S. financial markets. The Company...
Feb 01, 2018 04:30 pm ET
Retrophin to Present at the Leerink Partners 7th Annual Global Healthcare Conference
SAN DIEGO, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Thursday, February 15,...
Jan 08, 2018 07:00 am ET
Retrophin Provides Corporate Update and 2018 Outlook
Preliminary full-year 2017 revenue of approximately $155 million
Jan 05, 2018 08:00 am ET
Dec 28, 2017 04:30 pm ET
Retrophin to Present at the 36th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 28, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 11, 2018 at...
Nov 30, 2017 04:30 pm ET
Retrophin to Present at the BMO 2017 Prescriptions for Success Healthcare Conference
SAN DIEGO, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO 2017 Prescriptions for Success Healthcare Conference in New York City on Thursday, December 14,...
Nov 07, 2017 04:20 pm ET
Retrophin Reports Third Quarter 2017 Financial Results
Retrophin, Inc. (NASDAQ: RTRX) today reported its third quarter 2017 financial results and provided a corporate update.
Nov 03, 2017 06:40 pm ET
Nov 02, 2017 04:30 pm ET
Retrophin to Present at the Jefferies 2017 London Healthcare Conference
SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 London Healthcare Conference in London, UK on Thursday, November 16, 2017 at 1:20 p.m. GMT (8:20 a.m. ET)....
Nov 02, 2017 04:30 pm ET
Retrophin to Present at the Jefferies 2017 London Healthcare Conference
SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 London Healthcare Conference in London, UK on Thursday, November 16, 2017 at 1:20...
Sep 11, 2017 04:30 pm ET
Retrophin to Present at September Investor Conferences
SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at two upcoming investor conferences in New York City, including:...
Sep 05, 2017 08:00 am ET
Retrophin Announces Cooperative Research and Development Agreement with NCATS and NGLY1.org to Identify Potential Small Molecule Therapeutics for NGLY1 Deficiency
SAN DIEGO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that it has entered into a three-way Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for NGLY1 Deficiency. This rare and debilitating monogenic disease is characterized by developmental delays, seizures and an inability to produce tears; there are cur...
Aug 14, 2017 04:30 pm ET
Retrophin Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that its Compensation Committee granted inducement awards pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules on July 31, 2017, August 7, 2017 and August 14, 2017 consisting of stock options to purchase an aggregate of 65,000 shares to three new employees. Each stock option has an exercise price per share equal to the closing price of Retrophin's common stock on the date of grant, is a non-qualified stock option, has a 10-year term and will vest over four years, with one-fourth vesting on the one-y...
Aug 09, 2017 04:01 pm ET
Retrophin Reports Second Quarter 2017 Financial Results
Fosmetpantotenate (RE-024) Phase 3 trial underway in PKAN...
Jul 26, 2017 04:30 pm ET
Retrophin to Report Second Quarter 2017 Financial Results
SAN DIEGO, July 26, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2017 financial results on Wednesday, August 9, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET....
Jul 25, 2017 08:00 am ET
Retrophin Commences Patient Dosing in International, Registrational Phase 3 Trial of RE-024 in PKAN
SAN DIEGO, July 25, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been dosed in the FORT (FOsmetpantotenate Replacement Therapy) Study, an international, registrational Phase 3 clinical trial assessing the safety and efficacy of RE-024 (fosmetpantotenate) for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), a rare, genetic neurological disorder....
May 23, 2017 04:30 pm ET
Retrophin to Present at the Jefferies 2017 Global Healthcare Conference
SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET....
May 04, 2017 04:01 pm ET
Retrophin Reports First Quarter 2017 Financial Results
Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017...
Apr 20, 2017 04:30 pm ET
Retrophin to Report First Quarter 2017 Financial Results
SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.            ...
Apr 12, 2017 04:30 pm ET
Retrophin Appoints Ron Squarer to Board of Directors
SAN DIEGO, April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company’s Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule therapies....
Mar 23, 2017 05:10 pm ET
John A. Orwin Joins Retrophin Board of Directors
SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company’s Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc., a biopharmaceutical company focused on developing treatments for patients with conditions that are often overlooked and undertreated....
Mar 07, 2017 04:30 pm ET
Retrophin to Present at the Barclays Global Healthcare Conference
SAN DIEGO, March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET....
Feb 15, 2017 04:30 pm ET
Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report fourth quarter and full year 2016 financial results on Wednesday, March 1, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 5:00 p.m. ET....
Feb 13, 2017 04:30 pm ET
Retrophin Appoints William Rote Senior Vice President, Research and Development
SAN DIEGO, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced William “Bill” Rote, Ph.D. has been appointed senior vice president, research and development, effective immediately. Dr. Rote will oversee all aspects of the Company’s R&D organization, with special focus on the advancement of its pipeline, as well as discovery and translational research, regulatory affairs, and medical affairs. Dr. Rote will report to chief executive officer Stephen Aselage....
Jan 09, 2017 08:00 am ET
Retrophin Provides Corporate Update and 2017 Preview
FDA discussions on sparsentan planned for January; RE-024 advancing with Phase 3 trial for the treatment of PKAN...
Jan 04, 2017 04:30 pm ET
Retrophin Appoints Elizabeth Reed General Counsel
SAN DIEGO, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Elizabeth Reed has been appointed general counsel and corporate secretary, effective immediately. Ms. Reed will be responsible for overseeing the Company’s general legal, intellectual property, government affairs and corporate compliance functions, reporting to chief executive officer Stephen Aselage....
Nov 30, 2016 04:30 pm ET
Retrophin to Present at the BMO Capital Markets Healthcare Conference
SAN DIEGO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO Capital Markets Prescription for Success Healthcare Conference in New York City on Wednesday, December 14, 2016 at 10:30 a.m. ET....
Nov 10, 2016 04:05 pm ET
Retrophin Reaches Agreement with FDA under Special Protocol Assessment for Pivotal Trial Evaluating RE-024 in PKAN
SAN DIEGO , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it has reached an agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating RE-024, the Company’s novel investigational replacement therapy, for the treatment of pantothenate kinase-associated neurodegeneration (PKAN). The SPA indicates concurrence by the FDA that the design of the pivotal trial can adequately support a New Drug Application (NDA) seeking U.S. approval of RE-024 for the treatment of PKAN. The...
Nov 03, 2016 04:01 pm ET
Retrophin Reports Third Quarter 2016 Financial Results
Positive top-line results from DUET announced in September; additional data to be presented at ASN Kidney Week 2016...
Oct 21, 2016 11:03 am ET
Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016
SAN DIEGO, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that additional data from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis (FSGS) will be presented at the late-breaking High-Impact Clinical Trials oral session at the American Society of Nephrology (ASN) Kidney Week 2016. Positive top-line results from the DUET study were announced in September 2016. The Company and its collaborators will also present further supportive data from the sparsentan program, as well as observational cohort data characterizing ...
Oct 20, 2016 04:30 pm ET
Retrophin to Report Third Quarter 2016 Financial Results
SAN DIEGO, Oct. 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report third quarter 2016 financial results on Thursday, November 3, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET....
Oct 06, 2016 04:30 pm ET
Dr. Alvin Shih Departing Retrophin to Lead Biotechnology Start-Up
SAN DIEGO, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced Alvin Shih, M.D., will be stepping down from his position as executive vice president and head of research and development to become chief executive officer of a start-up biotechnology company. Dr. Shih will remain in his current role until October 31, 2016 and has agreed to serve as a consultant to Retrophin thereafter. The Company has initiated a search for a permanent successor. In the interim, chief executive officer Stephen Aselage will assume responsibility of the research and development organ...
Sep 30, 2016 04:30 pm ET
Retrophin Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 30, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that its Board of Directors has granted an inducement award pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules to Julio Gagne in connection with his employment as vice president, Program Management....
Sep 14, 2016 04:30 pm ET
Retrophin to Present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series
SAN DIEGO, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Alvin Shih, M.D., executive vice president and head of research & development, will present at the Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series in New York City on Wednesday, September 28, 2016 at 11:05 a.m. ET....
Sep 07, 2016 06:55 am ET
Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
    Combined sparsentan treatment group experienced 44.8 percent reduction of proteinuria, more than double the reduction of irbesartan; achieves statistical significance in primary efficacy endpoint...
Aug 15, 2016 08:30 am ET
Retrophin Appoints Neil McFarlane Chief Operating Officer
SAN DIEGO, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced Neil McFarlane has been appointed chief operating officer. In this newly created position, Mr. McFarlane will help guide the Company’s daily operations with principal responsibility for commercial operations, business development, patient services, and program management. Mr. McFarlane will report to chief executive officer Stephen Aselage....
Aug 04, 2016 04:01 pm ET
Retrophin Reports Second Quarter 2016 Financial Results
Second quarter revenues increased 38 percent year-over-year...
Jul 21, 2016 04:30 pm ET
Retrophin to Report Second Quarter 2016 Financial Results
SAN DIEGO, July 21, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced it will report second quarter 2016 financial results on Thursday, August 4, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET....
Jul 19, 2016 04:30 pm ET
Retrophin Appoints Roy D. Baynes, M.D., Ph.D., to Board of Directors
SAN DIEGO, July 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Roy D. Baynes, M.D., Ph.D., to its Board of Directors, effective immediately. Dr. Baynes currently serves as senior vice president of Global Clinical Development at Merck Research Laboratories....
Jun 23, 2016 06:00 am ET
Retrophin Announces New Data from Physician-Initiated Treatment with RE-024 at the 20th International Congress of Parkinson’s Disease and Movement Disorders
SAN DIEGO, June 23, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced new data from physician-initiated treatment with RE-024, the company’s novel investigational replacement therapy for pantothenate kinase-associated neurodegeneration (PKAN), a rare and life-threatening genetic condition characterized by a host of progressively debilitating movement disorders. Key findings suggest RE-024 was safe and well tolerated in two adults with PKAN who experienced clinically meaningful improvements, followed by stabilization of disease progression over 47 weeks of treatment....
Jun 20, 2016 04:30 pm ET
Retrophin Acquires Liquid Formulation of Ursodeoxycholic Acid
SAN DIEGO, June 20, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the signing of a definitive agreement to purchase the rights, titles, and ownership of a liquid formulation of ursodeoxycholic acid from Asklepion Pharmaceuticals, LLC. Retrophin intends to file a New Drug Application with the U.S. Food and Drug Administration for the liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis (PBC) in 2017....
May 26, 2016 04:30 pm ET
Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO, May 26, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the following upcoming investor conferences:...